52 results on '"Rawstron, Andy C."'
Search Results
2. Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells
3. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
4. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
5. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia
6. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation
7. Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts
8. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy
9. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells
10. Minimal residual disease is an independent predictor for 10-year survival in CLL
11. Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure
12. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
13. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis
14. Inherited genetic susceptibility to monoclonal B-cell lymphocytosis
15. Validation of Plasma Cell Immunophenotype As a Biomarker to Identify High-Risk Smoldering Myeloma
16. Novel Targeted Therapies and Their Impact on Survival from Multiple Myeloma (MM) and Chronic Lymphocytic Leukaemia (CLL) in the Real World
17. Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up
18. Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study
19. Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial
20. Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project
21. B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial
22. The Level of Residual CLL Objectively Predicts the Outcome of Patients Following FCR-Based Therapy with Sequential Benefits per Log Depletion and Improved Post-Treatment Monitoring
23. Variable Expression of Therapeutic Antibody Targets May Have Implications for Efficacy of Therapy in Myeloma and Waldenstrom Macroglobulinaemia
24. Minimal Residual Disease (MRD) in Myeloma: Independent Outcome Prediction and Sequential Survival Benefits per Log Tumour Reduction
25. Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour
26. Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL
27. CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (
28. An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).
29. Minimal Residual Disease Is a Predictor for Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia (CLL) That Is Independent of the Type or Line of Therapy.
30. Five-Year Follow-up of Monoclonal B-Cell Lymphocytosis (MBL) in Individuals with a Normal Blood Count: Expansion of the Abnormal B-Cell Compartment but No Progressive Disease.
31. Peripheral Blood Disease Monitoring in Marginal Zone Lymphoma Using Flow Cytometry
32. Over-Expression of IRF4 (MUM1) Protein Predicts Poorer Outcome in Myeloma Patients
33. Differential Protein Expression in MBL and CLL: LAIR1 Is a Powerful Surface Marker for Identifying Cases with Adverse Cellular Features.
34. Defining Complete Response in Multiple Myeloma: Role of the Serum Free Light Chain Assay and Multiparameter Flow Cytometry.
35. Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.
36. Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year.
37. Cyclooxygenase-2 (COX-2) in Multiple Myeloma: Prognostic Marker or Therapeutic Target?.
38. Abortive Plasma Cell Differentiation with Loss of Mature B-Cell Phenotype in a Subset of Patients with De Novo Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma: Relevance of cMYC Rearrangements.
39. Rapid and Sensitive Detection of Minimal Plasma Cell Populations Using Six-Colour Flow Cytometry.
40. Neoplastic Plasma Cells Are Demonstrable at Bone Marrow Sites Distant to Solitary Plasmacytoma of Bone and Predict for Progression to Multiple Myeloma.
41. Increased Expression of CD200 Antigen, a Potential Immunotherapeutic Target, Is Consistently Found in CLL Cells Irrespective of Biological Features.
42. Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).
43. Monoclonal B-Cell Lymphocytosis (MBL) and CLL Show Intraclonal Variation: Cases Classified as “Unmutated” Have the Greatest Clonal Diversity.
44. Disease Progression in Monoclonal B-Cell Lymphocytosis Is Independent of VH Mutation Status.
45. Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.
46. The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells
47. IgM myeloma with t(4;14)(p16;q32)
48. IgH Rearrangements and Mutational Status in Class-Switched IgG B-CLL.
49. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion
50. Interpretation of sequential minimal residual disease assessment in chronic lymphocytic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.